Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors

Effect of Pulse Fractions on Indices of Lipid, Carbohydrate and Energy Metabolism as Well as Oxidative Status in Overweight, Hyperlipidemic Individuals

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00839774

Enrollment

Registered

2009-02-10

Start date

2007-02-28

Completion date

2008-03-31

Last updated

2010-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Peas, Cardiovascular, Diabetes, Insulin, Insulin resistance, Abdominal fat

Brief summary

The purpose of this study is to determine if whole and fractionated yellow pea flour, administered at USDA recommended dosages (50 g/day), improve risk factors associated with cardiovascular disease and diabetes.

Interventions

OTHERWhole yellow pea flour

Whole pea flour was administered at 50 g/day.

OTHERFractionated pea flour

Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day

OTHERWhite wheat flour

White wheat flour will be administered at 50 g/day

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* BMI between 25 and 40 kg/m2 * Hypercholesterolemic

Exclusion criteria

* Smoking * Use of prescription and natural lipid lowering therapies * Myocardial infarction * Coronary artery bypass * Angina * Congestive heart failure, * Inflammatory bowel disease * Pancreatitis * Renal disease * Diabetes * Chronic alcohol usage (\> 2 drinks/day). * Cancer * Eating disorders * Expending \> 4000 kcal/week through exercise

Design outcomes

Primary

Measure	Time frame
Energy expenditure	During week 1 and week 4 of each treatment phase
body composition	Day 1 and Day 29 of each treatment phase
Antioxidant status	Day 1 & 2 and Day 28 & 29 of each treatment phase
Postprandial substrate utilization	—
Postprandial dietary fatty acid oxidation	—
Lipid levels	Day 1 & 2 and Day 28 & 29 of each treatment phase
Postprandial glucose response	During week 1 and week 4 of each treatment phase
Fasting Insulin	Day 1 & 2 and Day 28 & 29 of each treatment phase
Insulin homeostasis modeling assessment	Day 1 & 2 and Day 28 & 29 of each treatment phase

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026